Kiora Pharmaceuticals | 8-K: FY2025 Q2 EPS: USD -0.54
EPS: As of FY2025 Q2, the actual value is USD -0.54.
EBIT: As of FY2025 Q2, the actual value is USD -2.265 M.
Financial Highlights
Net Loss: Kiora Pharmaceuticals reported a net loss of $2.2 million for the second quarter of 2025, consistent with the net loss of $2.2 million in the second quarter of 2024.
Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2025 were $2.6 million, before recognizing $1.7 million in reimbursable expenses from Théa. This is an increase from $2.0 million in the second quarter of 2024, with $1.1 million in offsetting reimbursable expenses from Théa.
General and Administrative (G&A) Expenses: G&A expenses were $1.4 million for the second quarter of 2025, down from $1.5 million in the second quarter of 2024.
Cash and Cash Equivalents: The company ended the quarter with $20.7 million in cash, cash equivalents, and short-term investments.
Collaboration Receivables: Kiora recorded $1.2 million in collaboration receivables from Théa for reimbursable R&D expenses and $1.25 million in collaboration receivables from Senju related to the option fee.
Deferred Revenue: The company recorded deferred revenue of $1.25 million related to a non-refundable option fee from Senju.
Outlook / Guidance
Kiora Pharmaceuticals anticipates maintaining its cash runway into late 2027, which extends beyond the anticipated data readouts for the KLARITY and ABACUS-2 trials. The company is actively recruiting for its Phase 2 clinical trials, with strategic partnerships expected to enhance global commercialization efforts. The potential deal with Senju could be valued at up to $110 million plus royalties, contingent on the exercise of the option agreement.
